Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy. Biomol Biomed [Internet]. 2024 Apr. 24 [cited 2024 May 20];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10641